Hyperhomocysteinemia Beyond Supplementation: A Practical Clinical Approach to Resistant Cases
Abstract:
Hyperhomocysteinemia is a well-established and modifiable risk factor associated with cardiovascular disease, stroke, cognitive decline, and systemic inflammation. Conventional therapeutic approaches based on folate, vitamin B12, and vitamin B6 supplementation are widely implemented and frequently effective. However, a subset of patients presents persistent elevations in homocysteine levels despite adequate or supraphysiological concentrations of these cofactors. This paradox highlights the complexity of homocysteine metabolism and suggests the presence of functional metabolic dysregulation rather than simple nutrient deficiency. This narrative review provides a comprehensive and clinically oriented framework integrating biochemical pathways, conventional therapies, and advanced metabolic reasoning in cases of treatment resistance. Particular emphasis is placed on methylation imbalance, impaired transsulfuration, and the concept of functional metabolic blockade. A practical, physiology-based approach is proposed to guide clinicians in the management of refractory hyperhomocysteinemia.
KeyWords:
Hyperhomocysteinemia, Homocysteine metabolism, Methylation imbalance, Transsulfuration pathway, Refractory hyperhomocysteinemia, Functional metabolic blockade
References:
- Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke. JAMA. 2002;288(16):2015–22.
- Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med. 1998;338(15):1042–50.
- Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease. BMJ. 2002;325:1202.
- Stover PJ. One-carbon metabolism–genome interactions in folate-associated pathologies. J Nutr. 2009;139(12):2402–5.
- Stipanuk MH. Sulfur amino acid metabolism: pathways for production and removal of homocysteine and cysteine. Annu Rev Nutr. 2004;24:539–77.
- Tyagi SC. Homocysteine redox receptor and regulation of extracellular matrix components in vascular cells. Am J Physiol. 1998;274:C396–405.
- Humphrey LL, Fu R, Rogers K, et al. Homocysteine level and coronary heart disease incidence. Mayo Clin Proc. 2008;83(11):1203–12.
- Smith AD, Refsum H. Homocysteine, B vitamins, and cognitive impairment. Annu Rev Nutr. 2016;36:211–39.
- Martí-Carvajal AJ, Solà I, Lathyris D, et al. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev. 2017;8:CD006612.
- Clarke R, Halsey J, Lewington S, et al. Effects of lowering homocysteine levels with B vitamins. Arch Intern Med. 2010;170(18):1622–31.
- McNulty H, Dowey le RC, Strain JJ, et al. Riboflavin lowers homocysteine in MTHFR genotype. Am J Clin Nutr. 2006;84(4):863–8.
- Bottiglieri T. S-Adenosyl-L-methionine (SAMe): from the bench to the bedside. Am J Clin Nutr. 2002;76(5):1151S–1157S.
- Selhub J. Homocysteine metabolism. Annu Rev Nutr. 1999;19:217–46.